One step forward, one step sideways? Expanding research capacity for neglected diseases
Author:
Open Access
- 14 July 2010
- journal article
- research article
- Published by Springer Nature in BMC International Health and Human Rights
- Vol. 10 (1) , 20
Abstract
There is general agreement, including from the pharmaceutical industry, that current market based methods of generating research into the development of pharmaceutical products that are relevant for developing countries do not work. This conclusion is relevant not just for the most neglected diseases such as leishmaniasis but even for global diseases such as cancer and cardiovascular disease. Stimulating research will mean overcoming barriers such as patent thickets, poor coordination of research activities, exclusive licensing of new technologies by universities and the structural problems that inhibit conducting appropriate clinical trials in developing countries. In addition, it is necessary to ensure that the priorities for research reflect the needs of developing countries and not just donors. This article will explore each of these issues and then look at three emerging approaches to stimulating research -paying for innovation, priority review sales or vouchers and public-private partnerships, - and evaluate their strengths and weaknesses. All of the stakeholders agree that there is a pressing need for a major expansion in the level of R&D. Whatever that new model turns out to be, it will have to deal with the 5 barriers outlined in this paper. Finally, none of the three proposals considered here for expanding research is free from major limitations.Keywords
This publication has 26 references indexed in Scilit:
- A social explanation for the rise and fall of global health issuesBulletin of the World Health Organization, 2009
- Academic Patents and Access to Medicines in Developing CountriesAmerican Journal of Public Health, 2009
- Three Proposals for Rewarding Novel Health Technologies Benefiting People Living in Poverty. A Comparative Analysis of Prize Funds, Health Impact Funds and a Cost-Effectiveness/Competitive Tender TreatyPublic Health Ethics, 2008
- Scrooge and intellectual property rightsBMJ, 2006
- Donor funding priorities for communicable disease control in the developing worldHealth Policy and Planning, 2006
- Improving Access to Medicines in Poor Countries: The Role of UniversitiesPLOS Medicine, 2006
- Innovation in Biomedicine: Can Stem Cell Research Lead the Way to Affordability?PLOS Medicine, 2006
- Gates's grandest challenge: transcending technology as public health ideologyThe Lancet, 2005
- Ethical review of health research: a perspective from developing country researchersJournal of Medical Ethics, 2004
- Using Economic Evaluations to Make Formulary Coverage DecisionsPharmacoEconomics, 2000